## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: HOIKHMAN=1

In re Application of:
David HOIKHMAN et al
Appln. No.: 10/565,593
I.A. No.: PCT/IL04/000654

\$371 date: January 23, 2006
I.A. filed: July 19, 2004

Atty. Docket: HOIKHMAN=1

Confirmation No.: 2249

Art Unit: 1615

Examiner: Humera N. Sheikh

For: GELLAN GUM BASED ORAL CONTROLLED RELEASE DOSAGE FORMS -A NOVEL PLATFORM TECHNOLOGY FOR GASTRIC RETENTION

## REPLY TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENTS

Honorable Commissioner for Patents U.S. Patent and Trademark Office Randolph Building, Mail Stop Amendment 401 Dulany Street Alexandria, VA 22314

Sir:

Applicants are in receipt of the Office Action mailed August 18, 2009, and Applicants reply below. Attached is a petition for four (4) months' extension of time.

Restriction has first been required between the product (Group I) and the process (Group II). Applicants hereby respectfully and provisionally elect the product, Group I, without traverse and without prejudice.

The PTO has imposed three separate election of species requirements, and Applicants hereby respectfully and provisionally elect as follows, with traverse and without prejudice.

In re Appln of HOIKHMAN et al Appln. No. 10/565,593 Reply to Office Action mailed August 18, 2009 Reply dated January 15, 2010

- $\qquad \qquad \textbf{(1) Election of hydrophilic polymer:} \quad \textbf{(a) guar gum,} \\ \textbf{xanthan gum}$ 
  - (2) Election of active ingredient: (a) drug
- (3) Election of controlled release dosage form: (a) tablet, caplet, vegecap

The claims which read on the elected species are claims 1--3 and 5--10. (Only claim 4 is limited to a non-elected species).

The election of species requirement is traversed on the basis that the generic claims themselves define a single general inventive concept under PCT Rules 13.1 and 13.2, and the PTO has not established anything to the contrary.

Applicants now respectfully await the receipt of the results of a first examination on the merits.

Applicants have become aware of three additional citations, namely U.S. Patent 6,210,710; U.S. Patent 5,935,604; and U.S. Patent 6,207,180. A formal IDS will soon be filed.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant

Ву

Sheridan Neimark Registration No. 20,520

SN:ltm

G:\BN\P\Pyer\Hcikhmanl\Pto\2010-01-15 election.dcc Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528